Clinical Implication of Concurrent Amplification of MET and FGFR2 in Metastatic Gastric Cancer.

ABSTRACT:

Background

c-mesenchymal epithelial transition factor receptor (c-MET) and fibroblast growth factor receptor 2 (FGFR2) amplification have been identified as factors associated with advanced stage and poor prognosis in gastric cancer (GC). While they are typically considered mutually exclusive, concurrent amplifications have been reported in a small subset of GC patients.

Methods

in this retrospective study, we analyzed the clinical outcomes of GC patients with MET and FGFR2 amplification using the next-generation sequencing (NGS) database cohort at Samsung Medical Center, which included a total of 2119 patients between October 2019 and April 2021.

Results

Of 2119 cancer patients surveyed, the number of GC patients was 614 (29.0%). Out of 614 GC patients, 39 (6.4%) had

SUBMITTER: Byeon S 

PROVIDER: S-EPMC10740780 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature